Instituto Gulbenbenkian de Ciência, in partnership with Almeirim Municipality and the Group of Lezíria Health Centers, carried out a study in the elderly living in nursing homes, vaccinated with the Pfizer vaccine. The study measured antibodies against SARS-CoV- 2 before the vaccination, three to four weeks after the first dose and 3 weeks after the second dose. The results reveal that only 25% develop antibodies after the first dose, values ​​that reach 95% after the second dose. 5% of participants do not develop immunity after taking the vaccine. 

Check the latest news in the press about this study (in Portuguese):

in Público

in Observador

in RTP

in Expresso

in Jornal de Notícias

in Diário de Notícias

in Visão

in TVI